Cardiff Oncology CRDF shares are trading higher on Thursday after HC Wainwright & Co initiated coverage on the stock with a Buy rating and announced a $27 price target.
Cardiff Oncology Inc is a clinical-stage company with the singular mission of developing new treatment options for cancer patients. Its objective is to overcome resistance, extend duration of response and increase overall survival.
Cardiff Oncology shares traded up 10.07% to $13.23 on Thursday at the time of publication. The stock has a 52-week high of $18.12 and a 52-week low of 70 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
